New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas

Abstract excerpt

Abstract Two recent independent studies published in Nature show robust responses of clear cell renal cell carcinoma (ccRCC) cell lines, preclinical ccRCC xenograft models and, remarkably, a patient with progressive ccRCC despite receiving multiple lines of treatment, to the long-awaited, recently developed inhibitors of hypoxia-inducible factor 2-alpha (HIF2α). This commentary published in Endocrine-Related...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adrenal and Paraganglionic Tumors
• Share to Cancer, Hypoxia, and Metabolism
• Share to Neuroblastoma Research and Treatments